303 related articles for article (PubMed ID: 30212240)
1. An Improved Inhaled Mucolytic to Treat Airway Muco-obstructive Diseases.
Ehre C; Rushton ZL; Wang B; Hothem LN; Morrison CB; Fontana NC; Markovetz MR; Delion MF; Kato T; Villalon D; Thelin WR; Esther CR; Hill DB; Grubb BR; Livraghi-Butrico A; Donaldson SH; Boucher RC
Am J Respir Crit Care Med; 2019 Jan; 199(2):171-180. PubMed ID: 30212240
[TBL] [Abstract][Full Text] [Related]
2. A novel thiol-saccharide mucolytic for the treatment of muco-obstructive lung diseases.
Addante A; Raymond W; Gitlin I; Charbit A; Orain X; Scheffler AW; Kuppe A; Duerr J; Daniltchenko M; Drescher M; Graeber SY; Healy AM; Oscarson S; Fahy JV; Mall MA
Eur Respir J; 2023 May; 61(5):. PubMed ID: 37080569
[TBL] [Abstract][Full Text] [Related]
3. Mucolytics in cystic fibrosis.
Henke MO; Ratjen F
Paediatr Respir Rev; 2007 Mar; 8(1):24-9. PubMed ID: 17419975
[TBL] [Abstract][Full Text] [Related]
4. Mucins, mucus, and sputum.
Voynow JA; Rubin BK
Chest; 2009 Feb; 135(2):505-512. PubMed ID: 19201713
[TBL] [Abstract][Full Text] [Related]
5. Effects of laxative and N-acetylcysteine on mucus accumulation, bacterial load, transit, and inflammation in the cystic fibrosis mouse small intestine.
De Lisle RC; Roach E; Jansson K
Am J Physiol Gastrointest Liver Physiol; 2007 Sep; 293(3):G577-84. PubMed ID: 17615175
[TBL] [Abstract][Full Text] [Related]
6. Improved clearability of cystic fibrosis sputum with dextran treatment in vitro.
Feng W; Garrett H; Speert DP; King M
Am J Respir Crit Care Med; 1998 Mar; 157(3 Pt 1):710-4. PubMed ID: 9517580
[TBL] [Abstract][Full Text] [Related]
7. Airway mucus in pulmonary diseases: Muco-adhesive and muco-penetrating particles to overcome the airway mucus barriers.
Pangeni R; Meng T; Poudel S; Sharma D; Hutsell H; Ma J; Rubin BK; Longest W; Hindle M; Xu Q
Int J Pharm; 2023 Mar; 634():122661. PubMed ID: 36736964
[TBL] [Abstract][Full Text] [Related]
8. Oxidation increases mucin polymer cross-links to stiffen airway mucus gels.
Yuan S; Hollinger M; Lachowicz-Scroggins ME; Kerr SC; Dunican EM; Daniel BM; Ghosh S; Erzurum SC; Willard B; Hazen SL; Huang X; Carrington SD; Oscarson S; Fahy JV
Sci Transl Med; 2015 Feb; 7(276):276ra27. PubMed ID: 25717100
[TBL] [Abstract][Full Text] [Related]
9. Mucolytic treatment with N-acetylcysteine L-lysinate metered dose inhaler in dogs: airway epithelial function changes.
Tomkiewicz RP; App EM; Coffiner M; Fossion J; Maes P; King M
Eur Respir J; 1994 Jan; 7(1):81-7. PubMed ID: 8143836
[TBL] [Abstract][Full Text] [Related]
10. Mucoactive agents for airway mucus hypersecretory diseases.
Rogers DF
Respir Care; 2007 Sep; 52(9):1176-93; discussion 1193-7. PubMed ID: 17716385
[TBL] [Abstract][Full Text] [Related]
11. A glycopolymer improves vascoelasticity and mucociliary transport of abnormal cystic fibrosis mucus.
Fernandez-Petty CM; Hughes GW; Bowers HL; Watson JD; Rosen BH; Townsend SM; Santos C; Ridley CE; Chu KK; Birket SE; Li Y; Leung HM; Mazur M; Garcia BA; Evans TIA; Libby EF; Hathorne H; Hanes J; Tearney GJ; Clancy JP; Engelhardt JF; Swords WE; Thornton DJ; Wiesmann WP; Baker SM; Rowe SM
JCI Insight; 2019 Apr; 4(8):. PubMed ID: 30996141
[TBL] [Abstract][Full Text] [Related]
12. N-Acetylcysteine mucolysis in the management of chronic obstructive pulmonary disease.
Sadowska AM
Ther Adv Respir Dis; 2012 Jun; 6(3):127-35. PubMed ID: 22361928
[TBL] [Abstract][Full Text] [Related]
13. Mucoactive drugs and multiple applications in pulmonary disease therapy.
Hocquigny A; Hugerot H; Ghanem R; Haute T; Laurent V; Cogulet V; Montier T
Eur J Pharm Biopharm; 2024 Jan; 194():110-117. PubMed ID: 38048888
[TBL] [Abstract][Full Text] [Related]
14. Therapeutic aerosols and airway secretions.
Rubin BK
J Aerosol Med; 1996; 9(1):123-30. PubMed ID: 10160202
[TBL] [Abstract][Full Text] [Related]
15. Physiology and pathophysiology of human airway mucus.
Hill DB; Button B; Rubinstein M; Boucher RC
Physiol Rev; 2022 Oct; 102(4):1757-1836. PubMed ID: 35001665
[TBL] [Abstract][Full Text] [Related]
16. N-acetylcysteine enhances cystic fibrosis sputum penetration and airway gene transfer by highly compacted DNA nanoparticles.
Suk JS; Boylan NJ; Trehan K; Tang BC; Schneider CS; Lin JM; Boyle MP; Zeitlin PL; Lai SK; Cooper MJ; Hanes J
Mol Ther; 2011 Nov; 19(11):1981-9. PubMed ID: 21829177
[TBL] [Abstract][Full Text] [Related]
17. Pharmacological approaches to discovery and development of new mucolytic agents.
King M; Rubin BK
Adv Drug Deliv Rev; 2002 Dec; 54(11):1475-90. PubMed ID: 12458156
[TBL] [Abstract][Full Text] [Related]
18. Losartan Rescues Inflammation-related Mucociliary Dysfunction in Relevant Models of Cystic Fibrosis.
Kim MD; Baumlin N; Yoshida M; Polineni D; Salathe SF; David JK; Peloquin CA; Wanner A; Dennis JS; Sailland J; Whitney P; Horrigan FT; Sabater JR; Abraham WM; Salathe M
Am J Respir Crit Care Med; 2020 Feb; 201(3):313-324. PubMed ID: 31613648
[No Abstract] [Full Text] [Related]
19. Inhaled adrenergics and anticholinergics in obstructive lung disease: do they enhance mucociliary clearance?
Restrepo RD
Respir Care; 2007 Sep; 52(9):1159-73; discussion 1173-5. PubMed ID: 17716384
[TBL] [Abstract][Full Text] [Related]
20. An optimized protocol for assessment of sputum macrorheology in health and muco-obstructive lung disease.
Völler M; Addante A; Rulff H; von Lospichl B; Gräber SY; Duerr J; Lauster D; Haag R; Gradzielski M; Mall MA
Front Physiol; 2022; 13():912049. PubMed ID: 35991170
[No Abstract] [Full Text] [Related]
[Next] [New Search]
